Indonesia's top Islamic body approves China's Sinovac vaccine

Published - January 08, 2021 04:40 pm IST - JAKARTA

Indonesia's highest Islamic body on Friday gave its religious approval to China's Sinovac vaccine, paving the way for its distribution in the world's most populous Muslim nation.

The Indonesian Ulema Council announced that the COVID-19 vaccine is holy and halal, or fit for consumption by Muslims.

The head of the council's Fatwa Department Asorirun Niam Sholeh also said that the complete fatwa, or religious edict, related to the safety of the vaccine is still waiting for the green light from the Indonesian Food and Drug Authority.

The drug regulator said it would draw from data of the clinical trials in Brazil and Turkey, as well as own trial results before authorizing use of the vaccine.

Indonesia has had its own late-stage clinical trials of the vaccine, but with smaller pool size than Brazil with just 1,620 participants. The clinical trial research team is expected to report the results to the regulator and state-owned pharmaceutical firm Bio Farma soon.

If given conditional approval, President Joko Widodo said that he will receive the first shot next week, with some of the ministers and senior officials, followed health care workers and other public servants.

Indonesia has signed agreements with Sinovac for millions of doses of the vaccine, which requires two shots. Some 3 million doses have already arrived in Indonesia and are being distributed across the vast archipelago nation in preparation for rollout.

Indonesia also has agreements with other vaccine companies including Novavax and AstraZeneca, though none has arrived in the country yet.

Indonesia recorded the highest daily toll with 10,617 on Friday. It brings the total to 808,340. It also recorded 233 deaths in the last 24 hours, taking the toll to 23,753.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.